Shanghai Fosun Pharmaceutical (02196): Shenzhen Bio-pharmaceutical Industry Fund plans to invest 600 million yuan to participate in Fosun Kite's Series A financing.

Shanghai Fosun Pharmaceutical (02196) announced on October 17, 2025 that its holding subsidiary Fosun Kary and Shanghai Fosun Pharmaceutical Industry (a direct holding shareholder of Fosun Kary) have signed a "Capital Increase Agreement" with Shenzhen Biomedical Industry Fund to participate in Fosun Kary's Series A financing. The Shenzhen Biomedical Industry Fund plans to contribute a total of 600 million yuan in installments to subscribe for no more than a total of 524.437452 million yuan of additional registered capital of Fosun Kary. The funds raised from the Series A financing will be used for the operation and business development of Fosun Kary and/or its subsidiaries. To fully mobilize the enthusiasm and creativity of the core team of Fosun Kary, on October 17, 2025, Fosun Kary signed "Co-Investment Agreement" and "Co-Investment Platform Capital Increase Agreement" with 14 co-investors including current directors and core management of Fosun Kary, and co-investment platforms. The co-investors plan to collectively contribute 3.525 million yuan through the co-investment platform to subscribe for a total of 3.08107 million yuan of additional registered capital of Fosun Kary. The pre-investment valuation of this co-investment is consistent with the current capital increase. On the same day, Shenzhen Biomedical Industry Fund, Pingshan District Guiding Fund, co-investment platform, Fosun Kary and its existing shareholders also reached a "Shareholders Agreement" together. As some of the co-investors include several directors and senior management of the company, according to the rules of the Shanghai Stock Exchange, these individuals constitute related parties of the company, and their participation in this co-investment constitutes a related party transaction for the company. Among them, these related co-investors (Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Liu Yi, Mr. Xingli Wang, Mr. Wenjie Zhang, Ms. Feng Rongli, and Ms. Zhu Yue) plan to collectively contribute 1.246664 million yuan through the co-investment platform to subscribe for a total of 1.089664 million yuan of additional registered capital of Fosun Kary. At the same time, to effectively attract and retain core teams and key talents who have a significant impact on the business growth of the holding subsidiary Fosun Kary, inspire entrepreneurial passion, and help long-term development of the company, on October 17, 2025, the board of directors of the company and the shareholders' meeting of Fosun Kary respectively approved the adoption and implementation of an incentive plan. According to the plan, Fosun Kary plans to grant a total of no more than 93.219893 million yuan of incentive rights (including restricted shares and options) at a price of 0.76 yuan per 1 yuan of Fosun Kary's registered capital through the incentive platform, in batches to the intended incentive recipients; among them, the first batch will grant no more than 76.184870 million yuan of incentive rights. The equity incentive rights under the plan are sourced from a portion of Fosun Kary shares transferred by the company's holding subsidiary Shanghai Fosun Pharmaceutical Industry to the incentive platform. Since the first batch of incentive recipients include several directors and senior management of the company, according to the rules of the Shanghai Stock Exchange, these individuals constitute related parties of the company, and their participation in this equity incentive constitutes a related party transaction for the company. If all incentive recipients of the first batch receive and unlock all incentive rights, these related incentive recipients (Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Liu Yi, Mr. Xingli Wang, Mr. Wenjie Zhang, Ms. Feng Rongli, and Ms. Zhu Yue) can collectively contribute 9.694159 million yuan through the incentive platform to indirectly hold 12.755472 million yuan of Fosun Kary's registered capital.